Drug Trial Radar · NCT04223856
Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer
Last checked: Nov 20, 2026Latest source record: May 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
886
Actual
Start
Mar 30, 2020
Primary completion
Aug 8, 2023
Study completion Mar 1, 2028
Sponsor
- Lead sponsor
- Astellas Pharma Global Development, Inc.Astellas (ALPMY)
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC; Seagen Inc.
- First posted
- Jan 10, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being done to see how well two drugs (enfortumab vedotin and pembrolizumab) work together to treat patients with urothelial cancer. The study will compare these drugs to other drugs that are usually used to treat this cancer (standard of care). The patients in this study will have cancer that has spread from their urinary system to other parts of their body.
Conditions
- Urothelial Cancer
Interventions
Enfortumab vedotinDrug
Enfortumab vedotin administered as an IV infusion on Days 1 and 8 of every 3-week cycle
PembrolizumabDrug
IV infusion on Day 1 of every 3-week cycle
CisplatinDrug
administered as IV infusion on Day 1 of each 3-week cycle
CarboplatinDrug
Dosed according to local guidelines and will be administered as IV infusion on Day 1 of each 3-week cycle
GemcitabineDrug
IV infusion on Days 1 and 8 of every 3 week cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 by Blinded Independent Central Review (BICR)Time frame: From the date of randomization to first documentation of PD or death due to any cause, whichever occurred first (maximum exposure to treatment was up to 39.2 months)
- Overall Survival (OS)Time frame: From randomization to date of death due to any cause or censoring date, whichever occurred first (maximum exposure to treatment was up to 39.2 months)
Locations
260 sites in 25 countries. Site status is shown where the registry gives one.
Ironwood Cancer & Research Centers - Chandler
Chandler, Arizona
Arizona Oncology Associates PD - HOPE
Tucson, Arizona
Providence St Joseph Medical Center
Burbank, California
City of Hope National Medical Center
Duarte, California
University of California Los Angeles Medical Center
Los Angeles, California
University of California Irvine - Newport
Orange, California
Rocky Mountain Cancer Centers - Aurora
Aurora, Colorado
University of Colorado Hospital / University of Colorado
Aurora, Colorado
Cancer Centers of Colorado - Denver
Denver, Colorado
Yale Cancer Center
New Haven, Connecticut
Eastern CT Hematology and Oncology Associates
Norwich, Connecticut
Lombardi Cancer Center / Georgetown University Medical Center
Washington D.C., District of Columbia
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida
Winship Cancer Institute / Emory University School of Medicine
Atlanta, Georgia
Georgia Cancer Specialists / Northside Hospital Cancer Institute
Marietta, Georgia
Louisiana State University/ East Jefferson General Hospital
Metairie, Louisiana
Maine Health Cancer Care
Biddeford, Maine
Johns Hopkins Medical Center
Baltimore, Maryland
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada
New Mexico Cancer Center
Albuquerque, New Mexico
New York University (NYU) Cancer Institute
New York, New York
Mount Sinai Medical Center
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Vidant Medical Center
Greenville, North Carolina
The Cleveland Clinic
Cleveland, Ohio
Toledo Clinic Cancer Center
Toledo, Ohio
Hillman Cancer Center / University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
Saint Francis Hospital / Bon Secours - South Carolina
Greenville, South Carolina
West Cancer Center & Research Institute
Germantown, Tennessee
University of Texas Southwestern Medical Center
Dallas, Texas
UT Health East Texas Hope Cancer Center
Tyler, Texas
Huntsman Cancer Institute
Salt Lake City, Utah
University of Virginia
Charlottesville, Virginia
Seattle Cancer Care Alliance / University of Washington
Seattle, Washington
Site AR54008
Buenos Aire, Argentina
Site AR54011
CABA, Argentina
Site AR54005
Córdoba, Argentina
Site AR54006
La Rioja, Argentina
Site AR54004
Mendoza, Argentina
Site AR54001
Rosario, Argentina
Showing 40 of 260 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.